NASDAQ:REPL - Replimune Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.00
  • Forecasted Upside: 62.08 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$34.55
▼ -0.12 (-0.35%)
1 month | 3 months | 12 months
Get New Replimune Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REPL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$56.00
▲ +62.08% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $56.00, with a high forecast of $67.00 and a low forecast of $48.00. The average price target represents a 62.08% upside from the last price of $34.55.

Buy

The current consensus among 8 polled investment analysts is to buy stock in Replimune Group. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/24/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/19/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/18/2020
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/18/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/5/2021HC WainwrightBoost Price TargetBuy$58.00 ➝ $60.00Medium
i
Rating by R. Burns at HC Wainwright
2/4/2021SVB LeerinkLower Price TargetOutperform$57.00 ➝ $56.00Medium
i
11/17/2020BTIG ResearchInitiated CoverageBuy$60.00High
i
11/10/2020HC WainwrightBoost Price TargetBuy$54.00 ➝ $58.00Low
i
Rating by R. Burns at HC Wainwright
11/6/2020BMO Capital MarketsBoost Price TargetOutperform$51.00 ➝ $57.00High
i
11/2/2020Jefferies Financial GroupInitiated CoverageBuy$67.00High
i
10/15/2020BMO Capital MarketsBoost Price TargetPositive ➝ Outperform$40.00 ➝ $51.00High
i
10/15/2020BarclaysBoost Price TargetOverweight$29.00 ➝ $50.00High
i
Rating by Peter Lawson at Barclays PLC
10/15/2020HC WainwrightUpgradeNeutral ➝ Buy$25.00 ➝ $54.00High
i
Rating by R. Burns at HC Wainwright
10/15/2020SVB LeerinkBoost Price TargetOutperform$27.00 ➝ $44.00High
i
10/14/2020Roth CapitalBoost Price TargetBuy$30.00 ➝ $50.00High
i
10/14/2020Chardan CapitalBoost Price TargetBuy$30.00 ➝ $48.00High
i
Rating by Geulah Livshits at Chardan Capital
8/7/2020Chardan CapitalReiterated RatingBuy$30.00High
i
Rating by Geulah Livshits at Chardan Capital
8/7/2020SVB LeerinkBoost Price TargetOutperform$25.00 ➝ $27.00Low
i
7/1/2020HC WainwrightReiterated RatingBuy ➝ Neutral$25.00High
i
Rating by Robert Burns at HC Wainwright
6/4/2020BMO Capital MarketsBoost Price TargetOutperform$31.00 ➝ $40.00High
i
6/4/2020HC WainwrightReiterated RatingBuy$24.00 ➝ $25.00High
i
Rating by R. Burns at HC Wainwright
6/4/2020BarclaysBoost Price TargetOverweight$21.00 ➝ $25.00High
i
Rating by Peter Lawson at Barclays PLC
6/4/2020Chardan CapitalReiterated RatingBuy$29.00High
i
Rating by Geulah Livshits at Chardan Capital
6/3/2020WedbushReiterated RatingOutperformMedium
i
Rating by R. Driscoll at Wedbush
5/4/2020BarclaysInitiated CoverageOverweight$21.00High
i
Rating by Peter Lawson at Barclays PLC
2/13/2020Chardan CapitalReiterated RatingBuy$28.00Low
i
Rating by Geulah Livshits at Chardan Capital
1/21/2020HC WainwrightReiterated RatingBuy$26.00 ➝ $24.00High
i
Rating by Ram Selvaraju at HC Wainwright
11/20/2019WedbushLower Price TargetOutperform$30.00 ➝ $12.50Medium
i
11/11/2019Roth CapitalBoost Price TargetBuy$20.00 ➝ $30.00Low
i
Rating by T. Butler at Roth Capital
10/24/2019Chardan CapitalReiterated RatingBuy$28.00Low
i
Rating by Geulah Livshits at Chardan Capital
10/15/2019Chardan CapitalSet Price TargetBuy$28.00High
i
Rating by Geulah Livshits at Chardan Capital
9/30/2019HC WainwrightReiterated RatingBuy$26.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/4/2019Roth CapitalInitiated CoverageBuy$20.00High
i
Rating by T. Butler at Roth Capital
8/15/2019Chardan CapitalReiterated RatingBuy$28.00Medium
i
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$28.00Low
i
7/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$27.00 ➝ $26.00Low
i
7/8/2019HC WainwrightInitiated CoverageBuy ➝ Buy$26.00Low
i
Rating by R. Selvaraju at HC Wainwright
4/24/2019WedbushInitiated CoverageOutperform ➝ Outperform$24.00High
i
Rating by R. Driscoll at Wedbush
1/23/2019JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralHigh
i
8/14/2018SVB LeerinkInitiated CoverageOutperform$25.00Low
i
Rating by J. Chang at SVB Leerink LLC
8/14/2018BMO Capital MarketsInitiated CoverageOutperform$31.00Low
i
8/14/2018JPMorgan Chase & Co.Initiated CoverageOverweight$26.00Low
i
(Data available from 6/16/2016 forward)
Replimune Group logo
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $34.55
$33.23
$34.77

50 Day Range

MA: $33.93
$28.50
$38.97

52 Week Range

Now: $34.55
$18.40
$54.85

Volume

293,633 shs

Average Volume

366,348 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.53

Frequently Asked Questions

What sell-side analysts currently cover shares of Replimune Group?

The following Wall Street research analysts have issued research reports on Replimune Group in the last twelve months: Barclays PLC, BMO Capital Markets, BTIG Research, Chardan Capital, HC Wainwright, Jefferies Financial Group Inc., Roth Capital, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for REPL.

What is the current price target for Replimune Group?

8 Wall Street analysts have set twelve-month price targets for Replimune Group in the last year. Their average twelve-month price target is $56.00, suggesting a possible upside of 62.1%. Jefferies Financial Group Inc. has the highest price target set, predicting REPL will reach $67.00 in the next twelve months. Chardan Capital has the lowest price target set, forecasting a price of $48.00 for Replimune Group in the next year.
View the latest price targets for REPL.

What is the current consensus analyst rating for Replimune Group?

Replimune Group currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe REPL will outperform the market and that investors should add to their positions of Replimune Group.
View the latest ratings for REPL.

What other companies compete with Replimune Group?

How do I contact Replimune Group's investor relations team?

Replimune Group's physical mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company's listed phone number is 781-222-9600 and its investor relations email address is [email protected] The official website for Replimune Group is www.replimune.com.